Predicting nasopharyngeal carcinoma patient response to radiation therapy

Nasopharyngeal carcinoma (NPC) affects cells lining the nasopharynx. The majority of NPC cases can be cured by radiation therapy, however ~20% are resistant to radiation treatment.

In this issue of the Journal of Clinical Investigation, Yu-Sun Chang and colleagues at Chang Gung University sought to find a way to predict which individual cases of NPC would be sensitive to radiation therapy. The authors compared the levels of various serum factors between NPC patients that responded to radiation therapy and patients that were resistant to therapy. Patients that did not respond to radiation therapy had higher serum levels of the IL-6 family cytokine leukemia inhibitory factor (LIF), and that LIF levels were predictive of NPC patient response to radiation therapy. The researchers further demonstrated that LIF itself promotes NPC.

In the companion commentary, Micah Luftig from the Duke University School of Medicine discusses the implications of LIF as a predictor of NPC resistance to .

More information: Leukemia inhibitory factor promotes nasopharyngeal carcinoma progression and radioresistance, J Clin Invest. DOI: 10.1172/JCI63428
Heavy LIFting: tumor promotion and radioresistance in NPC, J Clin Invest. 2013;123(12):4999–5001. DOI: 10.1172/JCI73416

add to favorites email to friend print save as pdf

Related Stories

Surgeons support nonphysician screens for low back pain

Apr 12, 2013

(HealthDay)—Most spine surgeons are interested in a nonphysician clinician (NPC) model of care for screening of low back or low back-related leg pain for patients referred for a surgical assessment, according ...

Recommended for you

Many throat cancer patients can skip neck surgery

1 hour ago

A new study shows that patients with human papillomavirus (HPV) – the same virus associated with both cervical and head and neck cancer – positive oropharyngeal cancer see significantly higher rates of complete response ...

Five genes to predict colorectal cancer relapses

1 hour ago

Researchers at the Catalan Institute of Oncology-Bellvitge Biomedical Research Institute (ICO-IDIBELL), led by David Garcia-Molleví have identified 5 genes differentially expressed in normal accompanying ...

User comments